0001415889-24-015533.txt : 20240605 0001415889-24-015533.hdr.sgml : 20240605 20240605143739 ACCESSION NUMBER: 0001415889-24-015533 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240604 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hannah Brendan CENTRAL INDEX KEY: 0001929422 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 241021677 MAIL ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 form4-06052024_060635.xml X0508 4 2024-06-04 0001662774 Quince Therapeutics, Inc. QNCX 0001929422 Hannah Brendan C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 273 SOUTH SAN FRANCISCO CA 94080 false true false false CHIEF BUSINESS OFFICER AND COO 0 Common Stock 2024-06-04 4 M 0 56061 0.55 A 257616 D Employee Stock Option (right to buy) 0.55 2024-06-04 4 M 0 56061 0 D 2032-03-27 Common Stock 56061 47439 D The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. /s/ Brendan Hannah 2024-06-05